IRCT20200105046010N9 IRCT 2020-09-13 Tabriz University of Medical Sciences Study of bioequivalence of Levodopa/Carbidopa/Entecapone tablet 200/50/200mg Fanda Pharma (Staparkin 200/50/200mg) and foreign samples on 24 healthy Iranian volunteers. In- Vivo Bioequivalence study of Levodopa/Carbidopa/Entecapone tablet 200/50/200mg Fanda Pharma (Staparkin 200/50/200mg) with brand drugs (Stalevo 200/50/200mg Novartis, Germany) in Iranian healthy volunteers. 2020-09-24 anticipated 24 Complete https://irct.ir/trial/48914 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Other design features: Tow period / Tow sequence with a washout time, Randomization description: Individuals are randomly selected with advertising 24 volunteers categorized in two sequences randomly.the type of drug (Sample and Brand drug) will prescribe with lottery.The number of individuals will be randomly selected and the first twelve will be selected as the first sequence and the second twelve will be selected as the second sequence, Blinding description: This study is a blind side clinical trial (volunteers). Staparkin and Stalevo® are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence In this study the bioequivalence of test and brand of Staperkin will be evaluated.. Intervention 1: Intervention group: Single dose of levodopa / carbidopa / entocapone citalopram 200/200/200 mg tablets (TALEVO® 200/50 / 200mg. NOVARTIS, Germany) Pharmaceutical Company as a reference product. Intervention 2: Intervention group: Single dose of Levodopa / Kirby Dopa / Entapapon Citalopram 200/50/200 mg Fanda Pharmaceutical Company (STAPARKIN® 200/50/200) as a test product. No - There is not a plan to make this available Justification or reason for not sharing IPD is These date are as secure between researcher and related industries.